Nucleic-acid drugs have the potential to revolutionize how we treat a wide range of diseases. 1 Among these drugs, antisense oligonucleotides (ASOs) have attracted significant attention for their ability to provide precise control over translation. ASOs have several mechanisms of action, including RNase H-mediated degradation of mRNA bound to DNA-based ASOs, modulation of pre-mRNA processing, and steric hinderance of ribosome binding. This RNA-level intervention allows for a targeted approach to correct gene dysregulation associated with various pathological conditions, thus providing a specific and effective therapeutic strategy.